Innate Pharma
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $6,172 | $6,172 | $10,721 | $10,721 |
Gross Profit | -8,365 | -8,365 | -1,563 | -1,563 |
EBITDA | -12,781 | -12,781 | -5,198 | -5,198 |
EBIT | -13,156 | -13,156 | -6,135 | -6,135 |
Net Income | -12,382 | -12,382 | -4,644 | -4,644 |
Net Change In Cash | 6,172 | 6,172 | 10,721 | 10,721 |
Free Cash Flow | 1,376 | 1,376 | -10,567 | -10,567 |
Cash | 69,990 | 69,990 | 70,605 | 70,605 |
Basic Shares | 80,872 | 80,872 | 80,586 | 80,586 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $51,901 | $49,639 | $12,112 | $56,833 |
Gross Profit | -4,121 | -2,024 | -34,892 | 53,791 |
EBITDA | -1,839 | -61,295 | -43,229 | 43,105 |
EBIT | -6,930 | -65,719 | -47,798 | 33,720 |
Net Income | -7,570 | -99,103 | -59,136 | -70,747 |
Net Change In Cash | 51,901 | 49,639 | 12,112 | 56,833 |
Free Cash Flow | -34,909 | -20,276 | -59,787 | -63,089 |
Cash | 70,605 | 84,225 | 103,756 | 136,792 |
Basic Shares | 80,453 | 79,639 | 79,542 | 78,934 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-03-31 | $0 |
2023-12-31 | $0 |
2023-09-30 | $0 |
2023-06-30 | $0.02 |
